Keywords: gsk, doses, first, patient, ph, iii, syncria

GSK doses first patient in Ph III Syncria trial

Article | 23 February 2009

Print This

UK drug major GlaxoSmithKline has begun patient dosing in the first of five Phase III trials of the investigational glucagon-like ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in